Skip to content

Clinical trials

Completed Phase 3 Attention Deficit Disorder with Hyperactivity trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Attention Deficit Disorder with Hyperactivity Phase: Phase 3 Status: Completed Clear all

174 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20011
20022
20036
200415
200515
200613
200710
200811
20098
20107
201110
20125
20134
20148
20159
20164
201711
20183
20196
20204
20224
20233
20242
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed174

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Shire26
Eli Lilly and Company21
Supernus Pharmaceuticals, Inc.8
Otsuka Pharmaceutical Development & Commercialization, Inc.7
Rhodes Pharmaceuticals, L.P.7
Sumitomo Pharma America, Inc.7
Novartis5
Noven Therapeutics5
Alza Corporation, DE, USA4
University of Cincinnati4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Attention Deficit Disorder with Hyperactivity174
Spasm9
Oppositional Defiant Disorder7
Attention Deficit and Disruptive Behavior Disorders4
Anxiety Disorders3
Conduct Disorder3
Sleep Initiation and Maintenance Disorders3
Mental Disorders2
Adjustment Disorders1
Autism Spectrum Disorder1

Trials

Showing 1 to 25 of 174. Each trial links to its page on Pharma Observatory.

74 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.